Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 10.96M | 7.87M | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 1.54M | 795.00K | -222.00K | -484.00K | -368.00K | -103.00K |
EBITDA | -611.35M | -566.91M | -99.60M | -119.53M | -89.35M | -43.45M |
Net Income | -606.38M | -567.94M | -75.80M | -104.20M | -86.85M | -41.66M |
Balance Sheet | ||||||
Total Assets | 492.49M | 540.63M | 621.48M | 672.14M | 776.15M | 221.79M |
Cash, Cash Equivalents and Short-Term Investments | 461.68M | 502.69M | 611.21M | 661.01M | 765.39M | 215.75M |
Total Debt | 11.41M | 8.91M | 4.01M | 4.26M | 3.06M | 0.00 |
Total Liabilities | 73.03M | 76.84M | 16.36M | 17.07M | 30.15M | 6.71M |
Stockholders Equity | 419.46M | 463.79M | 605.12M | 655.08M | 746.00M | 215.08M |
Cash Flow | ||||||
Free Cash Flow | -157.54M | -130.57M | -68.07M | -96.48M | -68.47M | -36.67M |
Operating Cash Flow | -157.34M | -130.41M | -68.00M | -96.11M | -68.19M | -36.53M |
Investing Cash Flow | 169.34M | 122.70M | 8.92M | 63.46M | -454.67M | -70.32M |
Financing Cash Flow | 858.00K | 331.00K | 628.00K | 1.33M | 625.53M | 133.13M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
51 Neutral | $7.55B | 0.39 | -61.90% | 2.32% | 17.14% | 1.55% | |
49 Neutral | $879.33M | ― | -63.56% | ― | 270.02% | 32.69% | |
49 Neutral | $609.06M | ― | -79.02% | ― | -50.69% | 8.01% | |
48 Neutral | $515.91M | ― | 34.94% | ― | ― | ― | |
46 Neutral | $574.35M | ― | -33.48% | ― | -25.88% | -29.16% | |
45 Neutral | $660.11M | ― | -119.66% | ― | ― | -551.08% | |
40 Underperform | $272.58M | ― | -60.45% | ― | ― | 6.99% |
On February 12, 2025, Dr. Jerry Wang, CEO of AnHeart Therapeutics, a subsidiary of Nuvation Bio Inc., departed the company after achieving key goals, including regulatory approvals for taletrectinib in China and the U.S., and the integration of AnHeart Therapeutics post-merger. Dr. Wang’s departure was not due to any disagreements, and his role as CEO was deemed unnecessary following these accomplishments.